[{"orgOrder":0,"company":"EPI Health","sponsor":"Novan","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor-alpha 1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"EPI Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"EPI Health \/ Novan","highestDevelopmentStatusID":"15","companyTruncated":"EPI Health \/ Novan"},{"orgOrder":0,"company":"EPI Health","sponsor":"MC2 Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"EPI Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"EPI Health \/ MC2 Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"EPI Health \/ MC2 Therapeutics"},{"orgOrder":0,"company":"Novan","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Berdazimer Sodium","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Novan","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Berdazimer Sodium","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Novan","sponsor":"Oppenheimer & Co. Inc.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Berdazimer Sodium","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Oppenheimer & Co. Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Oppenheimer & Co. Inc."},{"orgOrder":0,"company":"Novan","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Berdazimer Sodium","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Cantor Fitzgerald","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Novan","sponsor":"Oppenheimer & Co. Inc.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Berdazimer Sodium","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Oppenheimer & Co. Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Oppenheimer & Co. Inc."},{"orgOrder":0,"company":"EPI Health","sponsor":"Sato Yakuhin Kogyo Co., Ltd","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor-alpha 1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"EPI Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"EPI Health \/ Sato Yakuhin Kogyo Co., Ltd","highestDevelopmentStatusID":"15","companyTruncated":"EPI Health \/ Sato Yakuhin Kogyo Co., Ltd"},{"orgOrder":0,"company":"Novan","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"WH602","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"Novan \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Novan \/ National Institutes of Health"},{"orgOrder":0,"company":"Novan","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Berdazimer Sodium","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Novan","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"Berdazimer Sodium","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Novan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Inapplicable"},{"orgOrder":0,"company":"Novan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Inapplicable"},{"orgOrder":0,"company":"Novan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Inapplicable"},{"orgOrder":0,"company":"Novan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Inapplicable"},{"orgOrder":0,"company":"Novan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Inapplicable"},{"orgOrder":0,"company":"Novan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Inapplicable"},{"orgOrder":0,"company":"Novan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Inapplicable"},{"orgOrder":0,"company":"Novan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Novan \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Novan \/ Inapplicable"},{"orgOrder":0,"company":"Novan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Inapplicable"},{"orgOrder":0,"company":"Novan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Inapplicable"},{"orgOrder":0,"company":"Novan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Inapplicable"},{"orgOrder":0,"company":"Novan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Inapplicable"},{"orgOrder":0,"company":"Novan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Inapplicable"},{"orgOrder":0,"company":"Novan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Inapplicable"},{"orgOrder":0,"company":"Novan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Inapplicable"},{"orgOrder":0,"company":"Novan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Inapplicable"},{"orgOrder":0,"company":"Novan","sponsor":"EPI Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"Nitric oxide donor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Novan \/ EPI Health","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ EPI Health"},{"orgOrder":0,"company":"EPI Health","sponsor":"MC2 Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"EPI Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"EPI Health \/ MC2 Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"EPI Health \/ MC2 Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by Novan

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Through the acquisition, Ligand will gain access to all the assets of Novan, including SB206 (berdazimer sodium gel), all other programs in development, the NITRICIL™ drug delivery technology, and the commercial assets of its EPI health business.

                          Product Name : SB206

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          September 27, 2023

                          Lead Product(s) : Berdazimer Sodium

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Ligand Pharmaceuticals

                          Deal Size : $15.0 million

                          Deal Type : Divestment

                          blank

                          02

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Through the acquisition, Ligand will gain access to all the assets of Novan, including SB206 (berdazimer sodium gel), all other programs in development, the NITRICIL™ drug delivery technology, and the commercial assets of its EPI health business.

                          Product Name : SB206

                          Product Type : Other Small Molecule

                          Upfront Cash : $15.0 million

                          July 17, 2023

                          Lead Product(s) : Berdazimer Sodium

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Ligand Pharmaceuticals

                          Deal Size : $15.0 million

                          Deal Type : Acquisition

                          blank

                          03

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : SB206 (berdazimer sodium), the active ingredient in berdazimer gel, 10.3% (SB206), is a new chemical entity, for the treatment of molluscum contagiosum is a potential first-in-class topical nitric oxide-releasing agent with positive Phase 3 data submitte...

                          Product Name : SB206

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 03, 2023

                          Lead Product(s) : Berdazimer Sodium

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Novan intends to use the net proceeds from the offering to fund its SB206 (berdazimer sodium), 10.3% development program activities, support sales and marketing efforts for the Company’s marketed products and for general working capital purposes.

                          Product Name : SB206

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          March 16, 2023

                          Lead Product(s) : Berdazimer Sodium

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : H.C. Wainwright & Co.

                          Deal Size : $6.0 million

                          Deal Type : Public Offering

                          blank

                          05

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Novan intends to use the net proceeds from the offering to fund its SB206 (berdazimer sodium), 10.3% development program activities, support sales and marketing efforts for the Company’s marketed products and for general working capital purposes.

                          Product Name : SB206

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          March 14, 2023

                          Lead Product(s) : Berdazimer Sodium

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : H.C. Wainwright & Co.

                          Deal Size : $6.0 million

                          Deal Type : Public Offering

                          blank

                          06

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Rhofade (oxymetazoline hydrochloride) cream is an FDA-approved prescription topical treatment that may reduce persistent facial redness by at least two grades, according to both doctor and patient scales that evaluated rosacea redness in two 29-day trial...

                          Product Name : Rhofade

                          Product Type : Other Small Molecule

                          Upfront Cash : $5.0 million

                          December 21, 2022

                          Lead Product(s) : Oxymetazoline Hydrochloride

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved FDF

                          Sponsor : Sato Yakuhin Kogyo Co., Ltd

                          Deal Size : $7.5 million

                          Deal Type : Licensing Agreement

                          blank

                          07

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Acquisition forward integrates Novan with complementary commercial infrastructure to drive commercial launch of SB206, subject to regulatory approval, for the treatment of molluscum contagiosum.

                          Product Name : Rhofade

                          Product Type : Other Small Molecule

                          Upfront Cash : $27.5 million

                          November 03, 2022

                          Lead Product(s) : Oxymetazoline Hydrochloride

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved FDF

                          Sponsor : Novan

                          Deal Size : $51.0 million

                          Deal Type : Acquisition

                          blank

                          08

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : WYNZORA Cream is a fixed dose combination of calcipotriene and betamethasone dipropionate used for the topical treatment of plaque psoriasis. Betamethasone dipropionate has anti-inflammatory effects resulting in decreased expression of key TNF-α, IL-17A...

                          Product Name : SB206

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 14, 2022

                          Lead Product(s) : Berdazimer Sodium

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : EPI Health

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : WYNZORA is a cream-based fixed dose combination of calcipotriene and betamethasone dipropionate for topical treatment of plaque psoriasis. It is based on PAD™ Technology, which enables stability of both calcipotriene and betamethasone dipropionate in a...

                          Product Name : Wynzora

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 15, 2022

                          Lead Product(s) : Calcipotriol,Betamethasone Dipropionate

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved FDF

                          Sponsor : MC2 Therapeutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Novan intends to use the net proceeds from the offering, together with existing cash, to fund research and development program activities, including seeking regulatory approval of its product candidate, SB206, as a treatment for molluscum contagiosum.

                          Product Name : SB206

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          September 06, 2022

                          Lead Product(s) : Berdazimer Sodium

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Oppenheimer & Co. Inc.

                          Deal Size : $15.0 million

                          Deal Type : Public Offering

                          blank